LucidQuest’s Post

Thoughts on this? >> Agios plans thalassemia filing in US after unveiling data in transfusion-dependent patients >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #healthcare #biotech #pharma

Thoughts on this? >> Ipsen and Genfit’s elafibranor secures FDA thumbs up in rare liver disease >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #pharma #biotech #healthcare

Thoughts on this? >> Ipsen and Genfit’s elafibranor secures FDA thumbs up in rare liver disease >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #pharmaceutical #productmarketing #biotech

Thoughts on this? >> Rivus posts a win for its experimental obesity drug in heart failure patients >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #productmarketing #healthcare #pharma

Thoughts on this? >> Rivus posts a win for its experimental obesity drug in heart failure patients >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #pharmaceutical #biotech #healthcare

Ever wondered why patients juggle three pills instead of one with the same ingredients? The same curiosity led us to explore the benefits of combining multiple drugs into one formulation, which makes drug administration more convenient for patients. In a systematic review of 109 studies, we compared Single-tablet combination therapies (STCTs) as well as fixed-dose combinations ([FDCs] of non-tablet formulations) with the equivalent active compounds and doses in loose-dose combinations (LDCs) across four evidence domains: clinical trials, real-world evidence (RWE), health-related quality of life (HRQoL) studies, and economic evaluations. Our findings? Patients on STCTs not only showed significantly higher adherence and persistence compared to LDCs but also enjoyed positive perks – think reduced need for add-on medications, better blood pressure control, and improved hemoglobin A1C. Additionally, FDCs emerged with cost savings associated with lower medical costs and reduced healthcare resource utilization. Intrigued? Dive into our recently published article here: https://lnkd.in/eZjkBzwT

❄ Efficacy problems are just the beginning when it comes to temp excursions for sensitive #DP. 😷 You could be looking at aggregates, sterility problems, and immunogenicity. Ana-Zeralda Canals Hamann at Debiopharm helps us out with some straightforward advice on how to prevent temperature excursions and what to do when they happen.

#BiolinkCapital, a global licensing platform under #ClinicalServiceCenter, offering high quality licensing-out & licensing-in services for drug development programs. #BiolinkAssetInformation: ILP100-INN emilimogene sigulatibac– #Lactobacillus expressing human #CXCL12 Indications: 1)Treatment of non-healing wounds in people with #diabetes； 2)Treatment of surgical wounds in patients with #prediabetes, diabetes and #obesity； 3)Other indications possible. -Status: Phase 2 clinical developments ongoing EU (CTA) and US (IND) -Collaboration Opportunities: license takeover, co-development. -Highlights: • Extensive RCT phase 1 trial concludes clean safety and 10 days faster time to complete wound healing. • Antimicrobial and kills multi drug resistant (MDR) bacteria. #BiolinkLicensingService #BiolinkLicensingProducts

Thanks to Moe Alsumidaie for his interview with Alex Greg Sturmer, CEO of Elysium Therapeutics, Inc., which was featured in The Clinical Trial Vanguard. Elysium is an emerging biopharmaceutical company that is establishing new standards of safety in the opioid industry by developing SMART™ (Safer Medicines Alleviate Risks and Trauma) products, first- and best-in-class medicines that address the limitations and dangers associated with opioids and overdose rescue agents to reduce suffering from opioid-use disorder, opioid overdose, and acute pain. Elysium's lead SMART opioid product candidate – oral-overdose protected (O2P™) hydrocodone – is being developed for the treatment of moderate-to-severe acute pain. Elysium is also developing its SMART rescue medicine, SOOPR™ (Synthetic Opioid Overdose Prevention and Reversal), a long-acting opioid antagonist specifically designed to address oral synthetic opioid, including fentanyl, overdose. Tens of thousands of unnecessary overdose deaths each year exemplifies the critical shortcomings of currently available rescue agents, including naloxone and nalmefene. https://lnkd.in/eGqSwPSM

#NEW OP-ED FROM THE BIOSIMILARS FORUM IN STAT ⬇️ 2023 was a watershed year for millions of patients across the U.S., but urgent steps must be taken in 2024 to deliver lower-cost #biosimilars to all those who need them. Read the full piece below: https://lnkd.in/emFxuUHx